Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00179361 · ClinicalTrials.gov registry record

Natural History of Oro-pharyngeal Cancer Precursors

A clinical trial, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
374
Enrollment target

NCT00179361: Completed study, sponsored by Albert Einstein College of Medicine.

NCT00179361 is a clinical trial that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 374 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00179361 has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
374 participants
Enrollment target

Study Summary

Oro-pharyngeal cancers can develop from squamous dysplastic precursor lesions, which occur in a subset of common white (leukoplakia), red (erythroplasia), or mixed oro-pharyngeal plaques. Known risk factors for oro-pharyngeal cancer include tobacco smoke, alcohol consumption, diet and, in a subset of tumors, human papillomavirus (HPV). Along the oro-pharyngeal disease continuum, there may be variations in gene expression precursor lesions as a result of exposure to smoking, alcohol and HPV. However, the components of gene expression that are most likely associated with tumorigenesis in these tissues are poorly understood. This study will focus upon early gene expression profiles in the oral cavity and oropharynx in subjects who have precursor lesions and have been exposed to the common risk factors for carcinoma development including smoking and HPV infection. This application is to conduct pilot testing and establish appropriate procedures for an international prospective cohort study of the natural history of oro-pharyngeal cancer precursors among men and women at high risk of oro-pharyngeal cancer at Montefiore Medical Center, Bronx-NY. Brush biopsy specimens will be used to collect a transepithelial sample of cells from oro-pharyngeal plaques, as well as normal tissue from defined regions of the oral and pharyngeal mucosa. Measurement of gene expression will employ novel high-throughput cDNA microarray analysis and PCR-based HPV DNA testing. Oro-pharyngeal dysplasia will be diagnosed using cytopathology. Under this application, we will assess our planned instruments and procedures on an initial sample of 40 subjects. This planning period will allow for precise identification of methodologies, standardization of instruments and assays to be utilized by additional participating centers in a subsequent application.

Trial Details

FieldValue
Enrollment Target 374 participants
Start Date 2004-11
Est. Completion 2014-07
Albert Einstein College of Medicine

175 total trials

What the finished NCT00179361 record still lists

NCT00179361 is an observational study that tracks outcomes without assigning an intervention. The registered 374 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00179361 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00179361 about?

NCT00179361 is a clinical study titled "Natural History of Oro-pharyngeal Cancer Precursors". Oro-pharyngeal cancers can develop from squamous dysplastic precursor lesions, which occur in a subset of common white (leukoplakia), red (erythroplasia), or mixed oro-pharyngeal plaques. Known risk factors for oro-pharyngeal cancer include tobacco smoke, alcohol consumption, diet and, in a subset o...

What is the current status of trial NCT00179361?

This trial is currently completed. The enrollment target is 374 participants. The study started on 2004-11. Estimated completion is 2014-07.

Who is sponsoring clinical trial NCT00179361?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03686124 · 375 participants · Phase 1

    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

  • NCT04059172 · 375 participants · Early Phase 1

    Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management

  • NCT04134923 · 375 participants

    Imaging Biomarkers in Preclinical and Symptomatic AD

  • NCT04569747 · 375 participants · Phase 2

    A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00179361, the US trial registry maintained by the National Library of Medicine. NCT00179361 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.